Dermata Therapeutics Inc (NASDAQ:DRMA) currently has a daily average trading volume of 341.05K but it saw 75951954 shares traded in last market. With a market cap of 7.71M USD, the company’s current market price of $1.42 came rising about 5.19 while comparing to the previous closing price of $1.35. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.67 and as low as $1.00. In the recent trading on the day, stock has struck highest price mark of $1.35 while lowest mark touched by it was $2.37.
Taking a look at 20-day trading activity of Dermata Therapeutics Inc (DRMA) gives us an average price of $1.2205, while its current price level is -78.70% below from 52-week high level whereas it is 42.00% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2127 while that of 200 days or SMA-200 reads an average of $1.5967. A closer look into the stock’s movement over the week reveals that its volatility is standing at 21.91% during that period while stretching the period over a month that decreases to 10.24%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 67.87 which implies that the stock is in neutral territory.
Over the week, DRMA’s stock price is moving 20.34% up while it is 19.33% when we observe its performance for the past one month. Year-to-date it is 5.19% up and over the past year, the stock is showing a downside performance of -77.20%.
The company is expected to be releasing its next quarterly report on 2025-Mar-16, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Dermata Therapeutics Inc’s total number of outstanding shares is 5.43M with 23.27% of that held by the insiders while 0.84% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -787.11% and return on equity (ROE) at -310.44%. Stock’s beta reads 0.49. Stock has a price to book (P/B) ratio of 2.29. Its return on asset (ROA) is -213.46% on average.
